You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Marburg Virus Prophylactic Medical Countermeasure
SBC: Flow Pharma, Inc. Topic: CBD18A002Through this STTR contract, we propose to evaluate the efficacy of our vaccine, FlowVax Marburg, in nonhuman primates (NHPs). This will be achieved through four Tasks. In Task 1, we will manufacture the vaccine in a quantity sufficient for the animal studies. In Task 2, we will perform MHC genotyping on a representative population of NHPs and, based on results, select a set of MHC-matched NHPs for ...
STTR Phase II 2020 Department of DefenseOffice for Chemical and Biological Defense -
Development of a Caregiver Application and AI-Enabled Intelligent Assistant to Support Families and Formal Care Providers in Caring for Persons with Alzheimer's Disease and Related Dementias
SBC: Whiplash Technology, Inc. Topic: NIAPROJECT ABSTRACT Family caregivers face daunting challenges in caring for persons with Alzheimer’s disease. Currently, there is no widely available mechanism to provide real-time, context sensitive support to informal AD caregivers that can address the specific care needs of each AD patient. To address this critical gap, we developed CareVirtue, an innovative web/mobile application for family ca ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
A Portable PET Insert System for Simultaneous TOF-PET and MR Brain Imaging
SBC: PETcoil, Inc. Topic: 101Project Summary Medical imaging technologies such as magnetic resonance imaging (MRI) and positron emission tomography (PET) have been widely used in studying the underlying mechanisms of mental illnesses and neurological disorders such as brain tumors, Alzheimer’s disease, epilepsy, and depression, etc. However, PET and MRI scans are almost always ordered as separate studies on separate machine ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Broad Spectrum Bitter Taste Antagonists Discovery
SBC: DISCOVERYBIOMED, INC. Topic: NIDCDPrincipal Investigators for Small Business: DiscoveryBioMed, Inc. (DBM) and Monell Chemical Senses Center Project Summary Abstract Bitter taste in foods and medicines presents a barrier to overcoming global public health challenges: food insecurity, poor nutritional health, and poor compliance with medication use, particularly among children and the elderly. Sugar and salt, the mainstays to addres ...
STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health -
Engineering a unique antibody for patients with RA
SBC: ABWIZ BIO INC Topic: NIAIDRA is one of the most common chronic autoimmune disorders that can lead to complete joint destruction and severe disability if untreated. There is no cure for RA and up to 50% of RA patients do not respond to anti-TNF therapies as circulating Th-17/IL-17 levels are highly elevated subsequent to TNF blockade. For this subset of RA patients, disruption of a novel pathway that impairs the synergy bet ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
HBI-002 to Prevent Anthracycline-Related Cardiotoxicity
SBC: Hillhurst Biopharmaceuticals, Inc. Topic: NHLBIPROJECT SUMMARY There is an urgent need for the development of approaches to prevent cardiotoxicity in cancer patients being treated with anthracyclines, an important class of drugs in the treatment of cancer (e.g. doxorubicin). Anthracycline treatment-related cardiotoxicity is a major clinical problem that severely impacts patient care and also limits dose and usage. More than a quarter of patien ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Integrated Platform for Mass-Spectrometric Studies of Protein Structure
SBC: PROTEIN METRICS INC Topic: 400Summary Technology for studying the higher order structure (HOS) and interactions of biomolecules is a highlighted NIGMS SBIR/STTR research topic. Mass-spectrometric methods for studying HOS include hydroxyl radical footprinting as well as chemical methods to covalently label amino acid side-chain functional groups, and also hydrogen/deuterium exchange (HDX) on protein backbone amides. These metho ...
STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health -
HBI-002 to Treat Ulcerative Colitis
SBC: Hillhurst Biopharmaceuticals, Inc. Topic: 300PROJECT SUMMARY There is an urgent need for the development of new approaches to treat patients suffering from Ulcerative Colitis (UC), which is estimated to impact approximately one million adults in the United States, leading to morbidity, heightened risk of cancer, and mortality. In multiple preclinical studies, we and others have defined the therapeutic potential of low-dose exogenous carbon m ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Reversal of Tau Pathology with MSUT2 siRNA Conjugates
SBC: DTx Pharma, Inc. Topic: NIAProject Summary Genetic and pathologic evidence in andapos;pureandapos; tauopathies such as Progressive Supranuclear Palsy (PSP), Corticobasilar Degeneration (CBD) and some cases of Fronto-temporal Dementia (FTD) directly implicate tau as causing neuronal cell death, while in Alzheimer’s Disease (AD) tau accumulation correlates with development and progression of cognitive impairment. Because of ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Nucleic acid-based formulation of cytomegalovirus-vectored HIV vaccines
SBC: TENDEL THERAPIES INC Topic: NIAIDThis grant is for translational development of a scalable, nucleic acid-based formulation of cytomegalovirus-vectored vaccines that can be distributed without a cold chain. HIV candidate vaccines that use cytomegalovirus (CMV) as delivery vector and immunomodulatory adjuvant have shown extraordinary promise. In our preliminary work, for example, a rhesus cytomegalovirus-vectored SIV vaccine lackin ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health